Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression
US8927705B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8927705-B2 |
| Application number | US-201213708185-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 7, 2012 |
| Priority date | Dec 18, 2008 |
| Publication date | Jan 6, 2015 |
| Grant date | Jan 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated double stranded nucleic acid comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein each said 5′ terminus comprises a 5′ terminal nucleotide and each said 3′ terminus comprises a 3′ terminal nucleotide, wherein: said first strand is 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) po…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
- C12N15/1135Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C12N15/113Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8927705B2 cover?
- The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modifi…
- Who is the assignee on this patent?
- Dicerna Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1135. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).